Midatech makes board change
This article was originally published in Scrip
Midatech Pharma has announced that Jeff Brown is stepping down from its board of directors, following the company's IPO, to pursue other business interests. The change is effective from 30 April 2015. Midatech, headquartered in Oxford, UK, has a pipeline of product candidates in clinical and preclinical development in the key therapeutic areas of diabetes, cancer and neurological/ophthalmological diseases. The company floated on the AIM Market of the London Stock Exchange in December 2014.
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.